Replies to post #31722 on $heff's $tation of $tocks & $olid DD

[Nickelback]

Early Detection of Cancer save lives!
The following article is courtesy of TheCleverBull.com. That is the guiding principal behind Biomoda, Inc. (OTC:BMOD), a cancer diagnostics company focused on the development and commercialization of cost-effective, non-invasive, accurate and reproducible diagnostic tests for the early detection of cancer.

The need for early diagnosis and prevention for cancer is now, as World Health Organization (WHO) predicts a 50% rise in cancer incidence by year 2020. As this epidemic continues to expand, new and innovative technologies will be needed which will triumph their predecessors. As is the case with Biomoda’s unique product, CyPath. CyPath is a product developed from technology licensed by Biomoda from the University of California and from Biomoda’s own patented technology. This is a cytology assay with the ability to differentiate normal cells from abnormal cells. CyPath’s initial cancer target is lung cancer; additional R&D is focused on addressing bladder and cervical cancers.

“Biomoda’s proprietary technology had previously shown 100% sensitivity and 100% specificity during internal testing on a small sample of patients.”